These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 26119486)

  • 1. Augmented renal clearance in critically ill patients: etiology, definition and implications for beta-lactam dose optimization.
    Sime FB; Udy AA; Roberts JA
    Curr Opin Pharmacol; 2015 Oct; 24():1-6. PubMed ID: 26119486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Augmented renal clearance, low β-lactam concentrations and clinical outcomes in the critically ill: an observational prospective cohort study.
    Huttner A; Von Dach E; Renzoni A; Huttner BD; Affaticati M; Pagani L; Daali Y; Pugin J; Karmime A; Fathi M; Lew D; Harbarth S
    Int J Antimicrob Agents; 2015 Apr; 45(4):385-92. PubMed ID: 25656151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Augmented renal clearance and therapeutic monitoring of β-lactams.
    Udy AA; De Waele JJ; Lipman J
    Int J Antimicrob Agents; 2015 Apr; 45(4):331-3. PubMed ID: 25665727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between augmented renal clearance, antibiotic exposure and clinical outcome in critically ill septic patients receiving high doses of β-lactams administered by continuous infusion: a prospective observational study.
    Carrié C; Petit L; d'Houdain N; Sauvage N; Cottenceau V; Lafitte M; Foumenteze C; Hisz Q; Menu D; Legeron R; Breilh D; Sztark F
    Int J Antimicrob Agents; 2018 Mar; 51(3):443-449. PubMed ID: 29180280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations.
    Udy AA; Varghese JM; Altukroni M; Briscoe S; McWhinney BC; Ungerer JP; Lipman J; Roberts JA
    Chest; 2012 Jul; 142(1):30-39. PubMed ID: 22194591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between augmented renal clearance and clinical outcomes in patients receiving β-lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial.
    Udy AA; Dulhunty JM; Roberts JA; Davis JS; Webb SAR; Bellomo R; Gomersall C; Shirwadkar C; Eastwood GM; Myburgh J; Paterson DL; Starr T; Paul SK; Lipman J; ;
    Int J Antimicrob Agents; 2017 May; 49(5):624-630. PubMed ID: 28286115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. β-Lactam therapeutic drug monitoring in the critically ill: optimising drug exposure in patients with fluctuating renal function and hypoalbuminaemia.
    Hayashi Y; Lipman J; Udy AA; Ng M; McWhinney B; Ungerer J; Lust K; Roberts JA
    Int J Antimicrob Agents; 2013 Feb; 41(2):162-6. PubMed ID: 23153962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged administration of β-lactam antibiotics - a comprehensive review and critical appraisal.
    Osthoff M; Siegemund M; Balestra G; Abdul-Aziz MH; Roberts JA
    Swiss Med Wkly; 2016; 146():w14368. PubMed ID: 27731492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients.
    Veiga RP; Paiva JA
    Crit Care; 2018 Sep; 22(1):233. PubMed ID: 30244674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of β-lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy.
    Economou CJP; Wong G; McWhinney B; Ungerer JPJ; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2017 May; 49(5):589-594. PubMed ID: 28341612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased β-Lactams dosing regimens improve clinical outcome in critically ill patients with augmented renal clearance treated for a first episode of hospital or ventilator-acquired pneumonia: a before and after study.
    Carrié C; Chadefaux G; Sauvage N; de Courson H; Petit L; Nouette-Gaulain K; Pereira B; Biais M
    Crit Care; 2019 Nov; 23(1):379. PubMed ID: 31775840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmented renal clearance in pediatric intensive care: are we undertreating our sickest patients?
    Dhont E; Van Der Heggen T; De Jaeger A; Vande Walle J; De Paepe P; De Cock PA
    Pediatr Nephrol; 2020 Jan; 35(1):25-39. PubMed ID: 30374606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept.
    Roberts JA; Ulldemolins M; Roberts MS; McWhinney B; Ungerer J; Paterson DL; Lipman J
    Int J Antimicrob Agents; 2010 Oct; 36(4):332-9. PubMed ID: 20685085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can changes in renal function predict variations in β-lactam concentrations in septic patients?
    Casu GS; Hites M; Jacobs F; Cotton F; Wolff F; Beumier M; De Backer D; Vincent JL; Taccone FS
    Int J Antimicrob Agents; 2013 Nov; 42(5):422-8. PubMed ID: 23993066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic drug monitoring of β-lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures.
    Wong G; Briscoe S; McWhinney B; Ally M; Ungerer J; Lipman J; Roberts JA
    J Antimicrob Chemother; 2018 Nov; 73(11):3087-3094. PubMed ID: 30137377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A narrative review of predictors for β-lactam antibiotic exposure during empirical treatment in critically ill patients.
    Abdulla A; Ewoldt TMJ; Purmer IM; Muller AE; Gommers D; Endeman H; Koch BCP
    Expert Opin Drug Metab Toxicol; 2021 Apr; 17(4):359-368. PubMed ID: 33463382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. β-lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: a structured review.
    Sinnollareddy MG; Roberts MS; Lipman J; Roberts JA
    Clin Exp Pharmacol Physiol; 2012 Jun; 39(6):489-96. PubMed ID: 22519600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous infusion vs. bolus dosing: implications for beta-lactam antibiotics.
    Mohd Hafiz AA; Staatz CE; Kirkpatrick CM; Lipman J; Roberts JA
    Minerva Anestesiol; 2012 Jan; 78(1):94-104. PubMed ID: 21730935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying "at-risk" patients for sub-optimal beta-lactam exposure in critically ill patients with severe infections.
    Abdul-Aziz MH; Lipman J; Roberts JA
    Crit Care; 2017 Nov; 21(1):283. PubMed ID: 29157264
    [No Abstract]   [Full Text] [Related]  

  • 20. Prolonged infusion of beta-lactam antibiotics for Gram-negative infections: rationale and evidence base.
    Abdul-Aziz MH; Portunato F; Roberts JA
    Curr Opin Infect Dis; 2020 Dec; 33(6):501-510. PubMed ID: 33009140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.